Literature DB >> 2502650

[Anti-phospholipid antibody with recurrent venous thromboembolism and severe autoimmune thrombocytopenia].

J Kienast1, H Ostermann, W Stenzinger, E M Kötter, J van de Loo.   

Abstract

A 51 year-old man with a history of deep venous thromboses and recurrent pulmonary embolism on long-term anticoagulant treatment was admitted to our department because of insidious onset thrombocytopenia. He had neither a history nor clinical signs of abnormal bleeding. On admission, the platelet count was reduced to 21 x 10(9)/l, platelet associated IgG was increased, and bone marrow specimens showed megakaryocytic hyperplasia. Platelet survival was slightly shortened with enhanced platelet sequestration in a normal size spleen. Laboratory evaluation after discontinuation of anticoagulant treatment revealed persisting prolongation of both the prothrombin time and the activated partial thromboplastin time which could be attributed to the presence of a lupus-type circulating anticoagulant. Further relevant laboratory findings included an elevated titer of IgG anti-cardiolipin antibodies and a reduced euglobulin clot lysis activity after venous occlusion due to increased plasminogen activator inhibitor activity. In recent years, it has become apparent that a striking correlation exists between the presence of antibodies to phospholipids and thromboembolic disease and immune thrombocytopenia respectively. The present case report on the association of these autoantibodies with both, recurrent venous thromboembolism and severe thrombocytopenia, supports the hypothesis that anti-phospholipid antibodies may play a crucial part in the pathogenesis of these clinical conditions. A reduced vascular fibrinolytic capacity may be involved in the thrombophilic state induced by anti-phospholipid antibodies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502650     DOI: 10.1007/bf01718033

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  19 in total

1.  A clinical study of the lupus anticoagulant.

Authors:  M A Schleider; R L Nachman; E A Jaffe; M Coleman
Journal:  Blood       Date:  1976-10       Impact factor: 22.113

2.  The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level.

Authors:  M Petri; M Rheinschmidt; Q Whiting-O'Keefe; D Hellmann; L Corash
Journal:  Ann Intern Med       Date:  1987-04       Impact factor: 25.391

3.  Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature.

Authors:  K Lechner; I Pabinger-Fasching
Journal:  Haemostasis       Date:  1985

4.  Pulmonary hypertension and systemic lupus erythematosus.

Authors:  R A Asherson; C M Oakley
Journal:  J Rheumatol       Date:  1986-02       Impact factor: 4.666

5.  A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma.

Authors:  J H Verheijen; E Mullaart; G T Chang; C Kluft; G Wijngaards
Journal:  Thromb Haemost       Date:  1982-12-27       Impact factor: 5.249

Review 6.  Lupus anticoagulants.

Authors:  S S Shapiro; P Thiagarajan
Journal:  Prog Hemost Thromb       Date:  1982

7.  Anticardiolipin antibodies in autoimmune thrombocytopenic purpura.

Authors:  E N Harris; A E Gharavi; U Hegde; G Derue; S H Morgan; H Englert; J K Chan; R A Asherson; G R Hughes
Journal:  Br J Haematol       Date:  1985-02       Impact factor: 6.998

8.  Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma.

Authors:  J H Verheijen; G T Chang; C Kluft
Journal:  Thromb Haemost       Date:  1984-07-29       Impact factor: 5.249

9.  Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody.

Authors:  E N Harris; R A Asherson; A E Gharavi; S H Morgan; G Derue; G R Hughes
Journal:  Br J Haematol       Date:  1985-02       Impact factor: 6.998

10.  Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus.

Authors:  M D Lockshin; M L Druzin; S Goei; T Qamar; M S Magid; L Jovanovic; M Ferenc
Journal:  N Engl J Med       Date:  1985-07-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.